| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6551620 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940328 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8496965 | SALIX | Pellet formulation for the treatment of the intenstinal tract |
Apr, 2018
(6 years ago) | |
| US8911778 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8337886 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8956647 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8865688 | SALIX | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(6 years from now) | |
Apriso is owned by Salix.
Apriso contains Mesalamine.
Apriso has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Apriso are:
- US8940328
- US8496965
- US8911778
- US8337886
- US8956647
- US6551620
Apriso was authorised for market use on 31 October, 2008.
Apriso is available in capsule, extended release;oral dosage forms.
Apriso can be used as for the maintenance of remission of ulcerative colitis in subjects 18 years of age and older, for the maintenance of remission of ulcerative colitis.
The generics of Apriso are possible to be released after 01 May, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 31, 2011 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis; For the maintenance of remission of ulcerative colitis in subjects 18 years of age and older
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APRISO family patents
